Tags

Type your tag names separated by a space and hit enter

Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne.
F1000Res. 2018; 7F

Abstract

The skin commensal Propionibacterium acnes, recently renamed Cutibacterium acnes, along with the other major pathophysiological factors of increased seborrhea, hyperkeratinization of the pilosebaceous unit, and inflammation, has long been implicated in the pathogenesis of acne. Recent advances have contributed to our understanding of the role of P. acnes in acne. Although there are no quantitative differences in P. acnes of the skin of patients with acne compared with controls, the P. acnes phylogenic groups display distinct genetic and phenotypic characteristics, P. acnes biofilms are more frequent in acne, and different phylotypes may induce distinct immune responses in acne. P. acnes plays a further important role in the homeostasis of the skin's microbiome, interacting with other cutaneous commensal or pathogenic microorganisms such as Staphylococcus epidermidis, Streptococcus pyogenes, and Pseudomonas species. In the era of increasing antimicrobial resistance, the selection of acne treatment targeting P. acnes and the prevention of antibiotic resistance play a key role in improving outcomes in acne patients and public health.

Authors+Show Affiliations

Department of Dermatology, Andreas Syggros Hospital, University of Athens, Athens, Greece.Department of Dermatology, Andreas Syggros Hospital, University of Athens, Athens, Greece.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30613388

Citation

Platsidaki, Eftychia, and Clio Dessinioti. "Recent Advances in Understanding Propionibacterium Acnes (Cutibacterium Acnes) in Acne." F1000Research, vol. 7, 2018.
Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Res. 2018;7.
Platsidaki, E., & Dessinioti, C. (2018). Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Research, 7. https://doi.org/10.12688/f1000research.15659.1
Platsidaki E, Dessinioti C. Recent Advances in Understanding Propionibacterium Acnes (Cutibacterium Acnes) in Acne. F1000Res. 2018;7 PubMed PMID: 30613388.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. AU - Platsidaki,Eftychia, AU - Dessinioti,Clio, Y1 - 2018/12/19/ PY - 2018/12/12/accepted PY - 2019/1/8/entrez PY - 2019/1/8/pubmed PY - 2019/3/7/medline KW - Priopionibacterium acnes KW - acne KW - antimicrobial resistance KW - biofilm KW - phylotypes JF - F1000Research JO - F1000Res VL - 7 N2 - The skin commensal Propionibacterium acnes, recently renamed Cutibacterium acnes, along with the other major pathophysiological factors of increased seborrhea, hyperkeratinization of the pilosebaceous unit, and inflammation, has long been implicated in the pathogenesis of acne. Recent advances have contributed to our understanding of the role of P. acnes in acne. Although there are no quantitative differences in P. acnes of the skin of patients with acne compared with controls, the P. acnes phylogenic groups display distinct genetic and phenotypic characteristics, P. acnes biofilms are more frequent in acne, and different phylotypes may induce distinct immune responses in acne. P. acnes plays a further important role in the homeostasis of the skin's microbiome, interacting with other cutaneous commensal or pathogenic microorganisms such as Staphylococcus epidermidis, Streptococcus pyogenes, and Pseudomonas species. In the era of increasing antimicrobial resistance, the selection of acne treatment targeting P. acnes and the prevention of antibiotic resistance play a key role in improving outcomes in acne patients and public health. SN - 2046-1402 UR - https://www.unboundmedicine.com/medline/citation/30613388/Recent_advances_in_understanding_Propionibacterium_acnes__Cutibacterium_acnes__in_acne_ L2 - https://f1000research.com/articles/10.12688/f1000research.15659.1/doi DB - PRIME DP - Unbound Medicine ER -